Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17183295 | 1.00 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707121 | 0.93 | HDAC1 (0.57) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707193 | 0.84 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183296 | 0.84 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183294 | 0.82 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707465 | 0.82 | HDAC1 (0.66) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183427 | 0.81 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183425 | 0.81 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL17183352 | 0.80 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL15707060 | 0.80 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914589-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S P A (IT) | 2017-08-30 | — | — | EP | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-9365541-B2 | Compounds for use in the treatment of parasitic diseases | IRBM—SCIENCE PARK S.P.A. (IT) | 2016-06-14 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM - SCIENCE PARK S.P.A. (IT) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299163-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 1/4885HDAC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.